Margins Soar 530 Bps, but the 351% PAT Jump Disguises Conservative Guidance

On paper, it's a blowout: PAT up 351% and EBITDA margins expanded 530 basis points. But dig into the call and you find a company playing a patient, multi-year hand. The headline profit jump is mostly a function of the Viyash merger—reported revenue is ₹946 Cr consolidated, but management pegged organic growth at 20%. ESOP charges of ₹19 Cr in Q1 (normalizing to ₹25–30 Cr for FY27) further mask the true run-rate. Meanwhile, FY27 guidance of 13–15% growth, maintained from the prior call, is where the real caution emerges.

The core tension: Viyash delivered 114.4% YoY revenue growth (₹946 Cr) but management claimed only 20% organic. That gap is the merger integration. The combined entity (Sequent + Viyash) is now reporting consolidated numbers; prior-year was Sequent alone. Within that consolidated 946, the company broke down strong region performance: domestic animal health +60%, US formulations +60% YoY, emerging markets +36% (volume-led). But isolating the organic contribution remains opaque—a credibility gap for analysts and holders tracking real momentum.

Post-merger, Viyash granted ESOP options to employees. Q1 FY27 expensed ₹19 Cr; management guided ₹150 Cr full-year FY27, normalizing to ₹25–30 Cr by FY28. This is non-cash (balance sheet, not cash flow impact) but material to P&L: it depresses reported PAT by ~24% in Q1 alone. Strip it out and adjusted PAT is ~₹60 Cr, still up sharply but a more honest organic read. The company's focus on true run-rate metrics (EBITDA, cash) rather than PAT is telling—they're aware the headline is noisy.

Companion animal strategy sharpened. BioForLife acquisition (Italy, 85-product portfolio, 85% vet clinic coverage) SPA signed; close expected in the coming months. Aspiration added: ₹150–200 Cr companion animal revenue by FY32 (15% of ₹1,000 Cr target). This is a bold M&A pivot vs. prior general portfolio breadth.

Patent cliff timeline explicit. High-potent oncology & first-to-file launches now clearly mapped: first revenue 2029, majority 2030+. Prior call lacked this specificity. Five to seven-year R&D gestation on all new molecules. This is the real upside story, but it's a patient-capital play requiring shareholders to own 5+ years of execution risk.

Margin confidence reaffirmed. 20–22% EBITDA margin target sustained despite heavy capex (₹250–300 Cr FY27). US formulations now at 34–35% EBITDA margins (vs. ~1% prior via vertical integration). Operational leverage post-merger is delivering, not just a one-time beat.

The market's own verdict on the print: initially bullish, then skeptical. Stock popped +0.59% on day 1 (delivery 53.5%) but faded to −2.24% by day 3, closing below the pre-result level of ₹261.45. At ₹255.65 as of August 14, the stock is 14.2% below its all-time high and trading below its 50-day average (₹265.81). RSI sits at neutral 47.2; volume trend is increasing, suggesting accumulation, not capitulation.

Ownership shift. FII increased 156 basis points to 4.50% (Q4 FY26: 2.94%), signaling institutional interest in the margin expansion and debt payoff story. DII, however, trimmed 424 basis points to 3.75% (Q4: 7.99%), suggesting domestic institutions are taking profits or waiting for clarity on near-term growth. Promoter stake unchanged at 61.31%—no insider moves near the highs.

The day-3 fade aligns with fundamental caution: the 13–15% FY27 guidance (softened from the implied 15%+ trajectory on current run-rate) signaled management's own uncertainty on near-term momentum. Investors initially cheered the margin beat, then reconsidered the patience required to realize the 2029+ upside. The FII accumulation suggests long-term players are buying the dip, while DII trimming hints at short-term traders exiting.